Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,824.74
-10.0803-0.55%
Number of Gainers:4
Number of Losers:15
Number of Flat:- -
PE:- -
High:1,831.29
Open:1,830.64
Low:1,800.68
Close:1,834.82
Volume:139.68M
Turnover:13.01B
Market Cap:1.48T
Float Cap:1.45T

Loading ...

Rpt-NASDAQ - Moderna to Join NASDAQ-100 Index Replacing Warner Bros. Discovery on October 9, 2026

THOMSON REUTERS
·
Oct 02

Aethlon Medical Shareholders Expand Capital Structure Flexibility

TIPRANKS
·
Oct 02

Novavax Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Aethlon Medical Holds Annual Shareholder Meeting

Reuters
·
Oct 02

Pfizer Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

EQ Resources (ASX:EQR) Could Be 44% Below Fair Value After Profit Turnaround

Simply Wall St.
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Pfizer Sued by Florida Attorney General Over Alleged Deceptive Marketing Practices

MT Newswires Live
·
Oct 01

Florida sues Pfizer over COVID vaccine marketing

TIPRANKS
·
Oct 01

Florida Attorney General: Files Lawsuit Against Pfizer and Its CEO Albert Bourla

THOMSON REUTERS
·
Oct 01

Gilead Sciences Announces Dividend of R$ 0.2394442440 Per Unit for Brgildbdr 000

Reuters
·
Oct 01

Moderna Stock Gets Sell Call As Oncology Hopes Face Valuation Test

Simply Wall St.
·
Oct 01

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

THOMSON REUTERS
·
Oct 01

Coty Names Kara Langan General Manager, U.S. Consumer Beauty Division

Reuters
·
Oct 01

Pfizer says Phase 2 study of tilrekimig met primary endpoint

TIPRANKS
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01